US physicians treating chronic kidney disease (CKD) in patients with diabetes have recently had two new therapies added to selection they can choose from.
In April, the FDA approved AstraZeneca’s SGLT-2 inhibitor Farxiga  in this setting (and simultaneously to treat CKD in patients without diabetes) and earlier this month the agency approved Bayer’s oral, non-steroidal mineralocorticoid receptor (MR) antagonist Kerendia .
Some experts have said Farxiga will benefit in CKD not only from its impressive clinical data but a ‘halo effect’ as this drug class continues to rack up wins in other indications (Eli Lilly and Boehringer Ingelheim’s Jardiance just hit its primary endpoint  in a Phase III study for the notoriously challenging indication of heart failure with preserved ejection fraction [HFpEF]).
To get a better idea of how these two therapies may evolve the treatment of CKD in diabetes patients we are running a snap-poll to US endocrinologists and general practitioners asking them the following questions…
Results and analysis will be published later this week for FirstWord Pharma PLUS subscribers and can be purchased by non-FirstWord Pharma PLUS subscribers. To be notified when they become available, click here